Boehringer Ingelheim Venture Fund has co-led a $21.8m round for ImCheck Therapeutics, established with the support of Satt Sud-Est.
France-based immuno-oncology therapy developer ImCheck Therapeutics has closed a €20m ($21.8m) series A round co-led by Boehringer Ingelheim Venture Fund, the corporate venturing arm of pharmaceutical firm Boehringer Ingelheim.
Venture capital firm Kurma Partners and private equity firm Idinvest Partners co-led the round, while investment firms Gimv and LSP also contributed.
Founded in 2015, ImCheck is working on therapeutic antibodies that will treat cancer and auto-immune diseases. The company’s technology is based on research by Daniel Olive, pofessor of immunology…